معرفی
Paul Haber is a Professor and Medical Director of Drug Health Services specializing in Addiction Medicine at the Central Clinical School of the University of Sydney. His research focuses on alcoholic liver disease, substance abuse, and pharmacotherapies for addiction. He supervises multiple PhD/Master’s students exploring topics like alcohol use disorder neurobiology, opioid treatment accessibility, and psychedelic therapies.
Key research interests include alcohol metabolism, hepatitis C, and the intersection of neurosciences with addiction. Recent work emphasizes opioid agonist treatment disparities, pharmacotherapy for alcohol/methamphetamine dependence, and genetic risk factors for alcohol-related cirrhosis.
Publications span New England Journal of Medicine, Neuropsychopharmacology, and Addiction, highlighting clinical trials on medications like baclofen, naltrexone, and novel compounds like FGF21 analogues. His work addresses treatment satisfaction in custodial settings, psychedelic-assisted therapy feasibility, and cannabis extract efficacy for chemotherapy side effects.
He leads studies on psychedelic therapies for alcohol use disorder and opioid substitution therapies. Collaborations include exploring cannabidiol’s neurobehavioral effects and the impact of socioeconomic factors on pandemic health outcomes.
